Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Mayne Pharma Group ( (AU:MYX) ).
Mayne Pharma Group Limited has announced a favorable outcome in its legal proceedings with Cosette Pharmaceuticals, Inc., regarding the proposed acquisition by Cosette. The Supreme Court of New South Wales ruled in favor of Mayne Pharma, dismissing Cosette’s claims. The company will proceed with the acquisition scheme, which is subject to certain conditions, including FIRB and court approvals. The scheme is expected to become effective on 23 October 2025, with shareholders receiving $7.40 per share on or around 3 November 2025. This development marks a significant step forward in Mayne Pharma’s strategic acquisition plans, potentially enhancing its market position and shareholder value.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing novel pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company is a leader in dermatology and women’s health and offers contract development and manufacturing services globally. With a 40-year track record, Mayne Pharma has been successful in developing and commercializing new oral drug delivery systems worldwide.
Average Trading Volume: 285,011
Technical Sentiment Signal: Buy
Current Market Cap: A$455M
Find detailed analytics on MYX stock on TipRanks’ Stock Analysis page.